Sensitive Mutation Detection Using TaqMan Liquid Biopsy dPCR Assays

Optimized solution for cancer research

Sensitive detection of low-frequency mutant alleles has extensive implications for cancer research. The accumulation of mutations in oncogenes or tumor suppressor genes is an important aspect of tumorigenesis. The TaqMan Digital PCR Liquid Biopsy assays, combined with the Oncomine cfDNA solutions, offer a comprehensive set of tools for liquid biopsy applications, and in the future may enable noninvasive techniques towards personalized medicine. 

The TaqMan dPCR Liquid Biopsy Assays have been wet-lab tested and guaranteed to perform on the Applied Biosystems QuantStudio 3D and Bio-Rad* QX-100 and QX-200 systems. Download the quick reference guides on how to use TaqMan dPCR Liquid Biopsy Assays for QuantStudio 3D or Bio-Rad QX-100™ and QX-200™ systems* today.

Optimized solution for cancer research

Since these mutations are usually present only in a very small number of cells, they require an assay that delivers high signal-to-noise ratios and low false-positive rates.

By combining TaqMan fluorogenic 5’ nuclease chemistry with digital PCR methodology, researchers are now able to detect low-frequency mutations. Applied Biosystems TaqMan dPCR Liquid Biopsy assays for research have been optimized to work with digital PCR and droplet digital PCR systems to achieve the high performance required to detect and quantify mutations present at very low frequencies.

Our sensitive mutation detection solution includes a set of wet lab-verified TaqMan dPCR Liquid Biopsy assays for research to detect and quantify the most common cancer-related mutations (e.g., EGFR, BRAF, KRAS, PIK3CA, JAK2, and others). These assays, designed using the full bioinformatics power of the TaqMan Assay design pipeline, allow researchers to quantify rare mutants at a prevalence of ≤0.1% (Figure 1).

How to order TaqMan dPCR Liquid Biopsy assays

Tracking mutations in cfDNA and CTCs

Luca Quagliata, MD, University Hospital, Basel, Switzerland, talks about his research tracking mutations in metastatic prostate cancer samples using cfDNA and CTCs.

Looking at tumor evolution with cfDNA

Professor José Luis Costa, PhD, IPATIMUP, discusses use of cfDNA to detect rare mutations in lung cancer research blood samples.

Digital PCR for Rare Mutation Analysis

Discover the importance of detecting rare mutations in cancer research and learn how to use the QuantStudio 3D rare mutation analysis solution for sensitive detection of rare mutations.

Overview of sensitive mutation detection using TaqMan dPCR Liquid Biopsy assays

  • Optimized digital PCR performance—wet lab–verified TaqMan assays targeting over 100 common cancer mutations
  • High sensitivity—detect and quantify rare mutant prevalence to ≤0.1%
  • Cost-effective and convenient—single-tube format includes both wild type and mutant alleles
  • Streamlined analysis—advanced algorithms for better quantification of rare mutations
  • Guaranteed performance—assay replaced or account credited if you are not satisfied
  • Custom design support—guidance available for Custom TaqMan SNP Genotyping assays on the QuantStudio 3D Digital PCR System that are not part of this wet lab–verified collection

Figure 1. Example of rare allele quantification of KRAS by digital PCR. The KRAS G12V mutation was detected with a Custom TaqMan SNP Genotyping Assay optimized for digital PCR on the QuantStudio 3D Digital PCR System. Each sample represents a fraction of mutant plasmid to wild type genomic DNA. The 0.1% target represents mutant genomic DNA from a mutant cell line in a wild type genomic DNA background. All samples were analyzed using QuantStudio 3D AnalysisSuite Cloud Software with the relative quantification module. 
A) Targeted mutation rate of 10%. The mutation detection rate was 10.384% with a confidence interval of 8.235 - 13.076%.
B) Targeted mutation rate of 1%. The mutation detection rate 1.393% with a confidence interval of 0.772 - 2.507%.
C) Targeted mutation rate of 0.1%. The mutation detection rate was 0.142% with a confidence interval of 0.064 - 0.310%.
D) Wild type control sample.

* Bio-Rad and Bio-Rad QX100(TM) and QX200 (TM) Droplet Digital PCR Systems are trademarks of Bio-Rad Laboratories, Inc., which is not affiliated with Thermo Fisher Scientific.  These statements have not been reviewed or endorsed by Bio-Rad. TaqMan is a registered trademark of Roche Molecular Systems, Inc., used under license.